DOCSLIB.ORG

A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa Vol. 5, 3411–3418, November 1999 Clinical Cancer Research 3411 A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa, and Paclitaxel followed by Mitoxantrone, Thiotepa, and Paclitaxel with Autologous Hematopoietic Cell Support for Metastatic Breast Cancer Wendy W. Hu,1 Gwynn D. Long,2 PBPCs were performed on an outpatient basis. The first Keith E. Stockerl-Goldstein, Laura J. Johnston, seven patients were randomized to receive alternate cycle G-CSF or placebo on day 11 of each cycle. Nelson J. Chao,2 Robert S. Negrin, and Including the initial pulse of cyclophosphamide, 67 Karl G. Blume (84%) of a planned 80 total courses of chemotherapy were Division of Bone Marrow Transplantation, Department of Medicine, delivered. Of the planned 64 cycles of high-dose combination Stanford University Medical Center, Stanford, California 94305 chemotherapy, 52 cycles (81%) were delivered. Treatment was discontinued for progressive disease (one patient) or ABSTRACT morbidity (five patients). Twelve of 16 patients completed at least three cycles of therapy. Nine patients completed all Dose-intensive chemotherapy appears to be important four cycles. One death resulted from fungal sepsis. In 20 in the treatment of patients with recurrent solid tumors. cycles delivered to the first seven patients, day 11 G-CSF Expanding upon our prior experience, we report the results versus placebo was administered, with a median WBC re- of our most recent approach to administering dose-intensive covery of 10 versus 13 days, respectively (P 5 0.048 in cycle therapy using four cycles of moderately high-dose chemo- 1). The median duration of response was almost 9 months, therapy with hematopoietic cell support for patients with and the median survival was 18 months after therapy. With metastatic breast cancer. This outpatient therapy includes a median follow-up of 1.5 years and longest follow-up of 4.2 high-dose melphalan, thiotepa, and paclitaxel for two cycles years, two patients continue to be without evidence of dis- followed by mitoxantrone, thiotepa, and paclitaxel for two ease. The 3-year event-free survival, freedom from progres- cycles, with each cycle supported with autologous peripheral sion, and overall survival are 19%, 20%, and 31%, respec- blood progenitor cells (PBPCs). tively. Between December 1994 and June 1996, 16 patients This four-cycle regimen of high-dose combination ther- with recurrent or refractory breast cancer were enrolled in apy supported with hematopoietic progenitor cells is feasi- this prospective study. They had received a median of two ble, but it is associated with a range of posttransplant com- previous chemotherapy regimens, with a median of nine plications. The efficacy of such a treatment would have to be prior cycles of chemotherapy. For mobilization of autolo- substantially superior to that of other currently available gous PBPCs, patients received cyclophosphamide, 4 g/m2, therapies, including single autologous transplant proce- followed by granulocyte colony-stimulating factor (G-CSF). dures, to justify the prolonged period of treatment, multiple PBPCs were collected by apheresis. Each day’s collection episodes of pancytopenia, and associated toxicities, including was divided into four equal fractions, and each fraction was infectious risks. G-CSF administration after each PBPC infused after each cycle of combination therapy. Cycles 1 infusion appears to accelerate time to neutrophil recovery and 2 consisted of melphalan, 80 mg/m2, thiotepa, 300 mg/ but does not affect red cell or platelet engraftment. m2, and paclitaxel, 200 mg/m2. Cycles 3 and 4 were com- prised of mitoxantrone, 30 mg/m2, and thiotepa and pacli- taxel at the same doses as in the first two cycles. The INTRODUCTION cyclophosphamide infusion was administered in the hospi- Much experience has been gleaned throughout decades of tal, whereas all subsequent infusions of chemotherapy and research into tumor growth kinetics and cytotoxic therapy. The observation of a specific log-kill curve for an individual che- motherapeutic drug led to the development of treatment schemes using combinations of agents, with each one potentially adding to the overall cell kill. Subsequently, the timing and Received 2/01/99; revised 7/21/99; accepted 8/6/99. sequence of chemotherapy, the method of drug delivery, dose The costs of publication of this article were defrayed in part by the escalation, and dose intensity have become important concepts payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to in the treatment of cancer. indicate this fact. Substantial data exist to support the importance of dose 1 To whom requests for reprints should be addressed, at Division of intensity (the amount of drug delivered per unit of time) in the Bone Marrow Transplantation, Stanford University Medical Center, 300 treatment of solid tumors (1–3). However, increasing dose in- Pasteur Drive, H1353, Stanford, CA 94305. Phone: (650) 723-0822; Fax: (650) 725-8950; E-mail: [email protected]. tensity to levels that require cytokine support has not been 2 Present address: Duke University Medical Center, 2400 Pratt Street unequivocally established as more efficacious than standard Suite 100, Box 3961, Durham, NC 27705. dose therapy in prolonging overall survival in the treatment of Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 1999 American Association for Cancer Research. 3412 Multiple Cycle Therapy for Metastatic Breast Cancer Fig. 1 Schematic of chemotherapy adminis- tration. Days between administration of cycles were scheduled every 21 days. metastatic breast cancer (4–9). Proposed reasons for these re- cyclophosphamide followed by G-CSF was used to mobilize sults include variable reporting of actual doses received and autologous PBPCs. Our present report describes this four-cycle insufficient dose escalation to achieve statistically significant regimen and treatment outcomes for women with metastatic improvements in survival. Bezwoda and colleagues (10) at- breast cancer. tempted to administer dose-intensive therapy in their random- ized study demonstrating improvement in survival outcomes for patients with newly diagnosed metastatic breast cancer . How- MATERIALS AND METHODS ever, this somewhat controversial study was criticized for its Patient Eligibility. Sixteen patients with recurrent lack of high-dose cyclophosphamide in the standard dose arm, breast cancer were enrolled in this study between January the use of an unusual combination chemotherapy regimen in the 1995 and June 1996. Patient eligibility criteria included the standard dose arm, the unbalanced dispensing of tamoxifen following: age ,65 years, Karnofsky performance status therapy, and the resulting surprisingly poor survivals therein. $80%, the absence of central nervous system metastasis, and Although this study suggested that the second course of high- demonstration of adequate organ function and HIV seroneg- dose therapy may have been necessary to achieve the superior ativity. Chemotherapy-responsive disease or minimal tumor results, the impact of this was not ascertained sufficiently. The volume was not criteria for eligibility. The risks and benefits phase III studies that have demonstrated improvement in out- of the therapy were explained to patients at the initial clinic come from high-dose therapy for patients with lymphoma (11) visit and again at enrollment when written consent was and multiple myeloma (12) have administered a peak dose of obtained. The clinical protocol was approved by the Admin- single course myeloablative therapy as consolidation after re- istrative Panel on Human Subjects in Medical Research at sponse to standard dose therapies. The role of sufficiently dose- Stanford University. The study schema is depicted in Fig. 1. intensive multiple-cycle therapy made possible by hematopoi- Patient characteristics are listed in Table 1. Patients were etic progenitor cell support has not yet been fully addressed assessed for toxicity and response after each cycle of high- (13–19), and the development of future clinical studies for this dose therapy. A patient could be taken off the study if she did question may depend upon the results of current randomized not demonstrate continued improvement of disease status studies using single courses of high-dose therapy. with each cycle of therapy based upon investigator discretion We have previously reported a pilot study that described and assessment of clinical status. administration of dose- intensive four-cycle therapy with hema- Collection of PBPCs. All patients underwent placement topoietic cell support (20). Patients received repetitive cycles of of a double-lumen tunnelled catheter (12 French Cook, Bloom- high-dose mitoxantrone, thiotepa, and cyclophosphamide. Each ington, IN) before the administration of high-dose cyclophos- cycle was supported with PBPCs3 that had been collected after phamide. Patients received cyclophosphamide at 4 g/m2 i.v. recovery from high-dose etoposide and G-CSF. We subse- over 2 h. They were discharged the following day and treated quently modified the regimen by escalating the doses of MTC with G-CSF (Amgen, Thousand Oaks, CA) at ;10 mg/kg be- and adding paclitaxel to the regimen (MTTC).4 However, 10 of ginning 24 h after the completion of cyclosphosphamide infu- 18 patients treated with MTTC experienced cyclophosphamide- sion. G-CSF was continued daily until the target number of related toxicity, including
Load more

Recommended publications
  • ASHP Guidelines on Handling Hazardous Drugs
    132 Drug Distribution and Control: Preparation and Handling–Guidelines ASHP Guidelines on Handling Hazardous Drugs ASHP published its first guidance on hazardous drugs (HDs) Because newer studies have shown that contamination in 1983 as part of the 1983–84 ASHP Practice Spotlight: Safe is widespread in healthcare settings and that more workers Handling of Cytotoxic Drugs.1,2 This was followed by tech- than previously thought are exposed, these guidelines should nical assistance bulletins in 1985 and 1990 and the ASHP be implemented wherever HDs are received, stored, pre- Guidelines on Handling Hazardous Drugs in 2006.3-5 The pared, transported, administered, or disposed.8-11 2006 guidelines were created to harmonize with the National Comprehensive reviews of the literature covering an- Institute for Occupational Safety and Health (NIOSH) Alert: ecdotal and case reports of surface contamination, worker ex- 6,9,12 Preventing Occupational Exposure to Antineoplastic and posure, and risk assessment are available from NIOSH, Other Hazardous Drugs in Health Care Settings issued in the Occupational Safety and Health Administration 13,14 15-20 2004.6 The ASHP 2006 HD guidelines were current to 2005. (OSHA), and individual authors. The primary goal In 2007, the United States Pharmacopeial Convention of this document is to provide recommendations for the safe revised United States Pharmacopeia (USP) chapter 797 handling of HDs. These guidelines represent the research (Pharmaceutical Compounding—Sterile Preparations)7 to and recommendations of many groups and individuals who harmonize with the NIOSH 2004 Alert. It became effective have worked tirelessly over decades to reduce the potential May 1, 2008, establishing many of the NIOSH recommenda harmful effects of HDs on healthcare workers.
    [Show full text]
  • NOV 1 72010 1.0 Submitter
    510(k) SUMMARY NOV 1 72010 1.0 Submitter Name Shen Wei (USA) Inc. Street Address 33278 Central Ave., Suite 102 Union City, CA. 94587 Phone No. (510)429-8692 Fax No. (510)487-5347 Date of Summary Prepared: 08/12/10 Prepared by: Albert Li 2.0 Name of the device: Glove Proprietary or Trade Name: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs Common Name: Exam gloves Classification Name: Patient examination glove, Specialty Chemotherapy'(per 21 CFR 880.6250 product code LZC) Classification Information: Class I Nitrile patient examination glove 8OLZC, powder-free and meeting all the requirements of ASTM D 631 9-O0a-05 and is tested with chemotherapy drugs according to ASTM D 6978-05. 3.0 Identification of the Legally Marketed Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera Regulatory Class I Nitrile patient examination Product code: 8OLZA 5 10(k): K092411 4.0 Description of the Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrite Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs meets all the requirements of ASTM D 6978-05, ASTM D63 19-00a(2005) and FDA 21 CFT 880.6250. 5.0 Intended Use of Device: Product: Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs A disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. This device is single use only.
    [Show full text]
  • Melphalan) for Injection, for Intravenous Use History of Serious Allergic Reaction to Melphalan Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------DOSAGE FORMS AND STRENGTHS----------------------- These highlights do not include all the information needed to use For Injection: 50 mg per vial, lyophilized powder in a single-dose vial for EVOMELA safely and effectively. See full prescribing information for reconstitution. (3) EVOMELA. ---------------------------CONTRAINDICATIONS---------------------------------- EVOMELA® (melphalan) for injection, for intravenous use History of serious allergic reaction to melphalan Initial U.S. Approval: 1964 WARNING: SEVERE BONE MARROW SUPPRESSION, ---------------------WARNINGS AND PRECAUTIONS-------------------------- HYPERSENSITIVITY, and LEUKEMOGENICITY See full prescribing information for complete boxed warning. • Gastrointestinal toxicity: Nausea, vomiting, diarrhea or oral mucositis may occur; provide supportive care using antiemetic and antidiarrheal • Severe bone marrow suppression with resulting infection or medications as needed. (2.1, 5.2) bleeding may occur. Controlled trials comparing intravenous (IV) • Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to melphalan to oral melphalan have shown more myelosuppression fetus and to avoid pregnancy . (5.6, 8.1, 8.3) with the IV formulation. Monitor hematologic laboratory • Infertility: Melphalan may cause ovarian function suppression or testicular parameters. (5.1) suppression. (5.7) • Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation
    [Show full text]
  • Refractory Multiple Myeloma Patients: a Meta-Analysis and Systematic Review
    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Arsenic trioxide-based therapy in relapsed/ refractory multiple myeloma patients: a meta-analysis and systematic review Xuepeng He Abstract: Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of Kai Yang malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. Peng Chen Although some newly approved drugs (thalidomide, lenalidomide, and bortezomib) demonstrate Bing Liu significant benefit for MM patients with improved survival, all MM patients still relapse. Arsenic Yuan Zhang trioxide (ATO) is the most active single agent in acute promyelocytic leukemia, the antitumor Fang Wang activity of which is partly dependent on the production of reactive oxygen species. Due to its multifaceted effects observed on MM cell lines and primary myeloma cells, Phase I/II trials have Zhi Guo been conducted in heavily pretreated patients with relapsed or refractory MM. Therapy regimens Xiaodong Liu varied dramatically as to the dosage of ATO and monotherapy versus combination therapy with Jinxing Lou For personal use only. other agents available for the treatment of MM. Although ATO-based combination treatment Huiren Chen was well tolerated by most patients, most trials found that ATO has limited effects on MM Department of Hematology, patients. However, since small numbers of patients were randomized to different treatment General Hospital of Beijing arms, trials have not been statistically powered to determine the differences in progression-free Military Area of PLA, Beijing, People’s Republic of China survival and overall survival among the experimental arms.
    [Show full text]
  • Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, And
    ANTICANCER RESEARCH 33: 1989-2000 (2013) Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, and Gastric Cancer Cell Lines in a Short-term Exposure Model of Chemosaturation Therapy by Percutaneous Hepatic Perfusion RAJNEESH P. UZGARE, TIMOTHY P. SHEETS and DANIEL S. JOHNSTON Pharmaceutical Research and Development, Delcath Systems, Inc., Queensbury, NY, U.S.A. Abstract. Background: The goal of this study was to candidates for use in the CS-PHP system to treat patients determine whether liver, gastric, or colonic cancer may be with gastric and colonic metastases, and primary cancer of suitable targets for chemosaturation therapy with the liver. percutaneous hepatic perfusion (CS-PHP) and to assess the feasibility of utilizing other cytotoxic agents besides Chemotherapeutic molecules exert beneficial clinical effects melphalan in the CS-PHP system. Materials and Methods: by inhibiting cell growth or by inducing cell death via Forty human cell lines were screened against three cytotoxic apoptosis. They can be divided into several categories based chemotherapeutic agents. Specifically, the dose-dependent on their mechanisms of action. The chemotherapeutic agent effect of melphalan, oxaliplatin, and paclitaxel on melphalan hydrochloride, which has been approved by the proliferation and apoptosis in each cell line was evaluated. US Food and Drug Administration and is used in the These agents were also evaluated for their ability to induce treatment of multiple myeloma and ovarian cancer, is a apoptosis in normal primary human hepatocytes. A high- derivative of nitrogen mustard that acts as a bifunctional dose short-term drug exposure protocol was employed to alkylating agent. Melphalan causes the alkylation of DNA at simulate conditions encountered during CS-PHP.
    [Show full text]
  • Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs!
    YOU’RE FIGHTING CANCER. Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs! PURPLE NITRILE-XTRA* Gloves and HALYARD* Procedure Gowns for Chemotherapy Use have been tested It’s 52 vs. You. for resistance to 52 chemotherapy drugs.† Arsenic Trioxide (1 mg/ml) Cyclophosphamide (20 mg/ml) Fludarabine (25 mg/ml) Mitomycin (0.5 mg/ml) Temsirolimus (25 mg/ml) Azacitidine (Vidaza) (25 mg/ml) Cytarabine HCl (100 mg/ml) Fluorouracil (50 mg/ml) Mitoxantrone (2 mg/ml) Trastuzumab (21 mg/ml) Bendamustine (5 mg/ml) Cytovene (10 mg/ml) Fulvestrant (50 mg/ml) Oxaliplatin (2 mg/ml) ThioTEPA (10 mg/ml) Bleomycin Sulfate (15 mg/ml) Dacarbazine (10 mg/ml) Gemcitabine (38 mg/ml) Paclitaxel (6 mg/ml) Topotecan HCl (1 mg/ml) Bortezomib (Velcade) (1 mg/ml) Daunorubicin HCl (5 mg/ml) Idarubicin (1 mg/ml) Paraplatin (10 mg/ml) Triclosan (1 mg/ml) Busulfan (6 mg/ml) Decitabine (5 mg/ml) Ifosfamide (50 mg/ml) Pemetrexed (25 mg/ml) Trisenox (0.1 mg/ml) Carboplatin (10 mg/ml) Docetaxel (10 mg/ml) Irinotecan (20 mg/ml) Pertuzumab (30 mg/ml) Vincrinstine Sulfate (1 mg/ml) Carfilzomib (2 mg/ml) Doxorubicin HCl (2 mg/ml) Mechlorethamine HCl (1 mg/ml) Raltitrexed (0.5 mg/ml) Vinblastine (1 mg/ml) Carmustine (3.3 mg/ml)† Ellence (2 mg/ml) Melphalan (5 mg/ml) Retrovir (10 mg/ml) Vinorelbine (10 mg/ml) Cetuximab (Erbitux) (2 mg/ml) Eribulin Mesylate (0.5 mg/ml) Methotrexate (25 mg/ml) Rituximab (10 mg/ml) Zoledronic Acid (0.8 mg/ml) Cisplatin (1 mg/ml) Etoposide (20 mg/ml) † Testing measured no breakthrough at the Standard Breakthrough Rate of 0.1ug/cm2/minute, up to 240 minutes for gloves and 480 minutes for gowns, except for carmustine.
    [Show full text]
  • 1 Contents of Online Supporting Information Etable 1. Study
    Contents of Online Supporting Information eTable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone eTable 2. Study characteristics of head to head trials of intravesical therapy eTable 3. Study characteristics of trials comparing dose or duration of a single drug eTable 4. Summary of the evidence eFigure 1. Literature flow diagram eFigure 2. Meta-analysis of doxorubicin versus no intravesical therapy: Risk of recurrence eFigure 3. Meta-analysis of epirubicin versus no intravesical therapy: Risk of recurrence References for the Supplement 1 eTable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone Author, Year Risk of Bias Inclusion Criteria Population Characteristics Intervention Followup Duration Abrams, 19811 Histologically confirmed All characteristics reported for A: Doxorubicin, 50 mg (in 50 6 months for all patients. High superficial bladder tumor; all randomized patients, not mL saline). Single instillation, Recurrent only, with presence the groups analyzed: within 24 hours of TURBT of tumors at both of two Age, mean (years): 72 vs. 68 (n=30). previous endoscopies 12 Male: 70% vs. 79% months and 6 months before Recurrent bladder cancer: B: No adjuvant treatment. entry into trial; Stages Ta or 100% vs. 100% TURBT alone (n=30). T1; Included grades not Ta: 73% vs. 77% specified, but "well" and T1: 27% vs. 23%; "moderate" differentiation included. Akaza, 19872 Histologically proven Age, mean (years): 62.3 vs. A: Doxorubicin, 30 mg (in 30 Maximum (years): 5; Not [Study One] superficial bladder cancer 62.9 vs. 62.9 vs. 62.9 mL saline). Total 8 instillations: reported as median/mean, nor (followup of Niijima, (primary or recurrent).
    [Show full text]
  • Leukemia Cells Are Sensitized to Temozolomide, Carmustine and Melphalan by the Inhibition of O6‑Methylguanine‑DNA Methyltransferase
    ONCOLOGY LETTERS 10: 845-849, 2015 Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O6‑methylguanine‑DNA methyltransferase HAJIME ARAI, TAKAHIRO YAMAUCHI, KANAKO UZUI and TAKANORI UEDA Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui 910-1193, Japan Received August 8, 2014; Accepted April 13, 2015 DOI: 10.3892/ol.2015.3307 Abstract. The cytotoxicity of the monofunctional alkylator, Introduction temozolomide (TMZ), is known to be mediated by mismatch repair (MMR) triggered by O6-alkylguanine. By contrast, the Alkylating agents comprise a major class of chemo- cytotoxicity of bifunctional alkylators, including carmustine therapeutic agents, widely used in various types of cancer, (BCNU) and melphalan (MEL), depends on interstrand cross- including leukemia (1,2). There are two types of alkyl- links formed through O6-alkylguanine, which is repaired by ating agents: monofunctional and bifunctional agents. nucleotide excision repair and recombination. O6-alkylguanine Bifunctional alkylating agents include cyclophosphamide, is removed by O6-methylguanine-DNA methyltransferase ifosfamide, melphalan (MEL) and carmustine (BCNU; (MGMT). The aim of the present study was to evaluate the cyto- also known as 1,3-bis(2-chloroethyl)-1-nitrosourea). toxicity of TMZ, BCNU and MEL in two different leukemic Monofunctional agents include temozolomide [TMZ; cell lines (HL-60 and MOLT-4) in the context of DNA repair. also known as 3,4-dihydro-3-methyl-4-oxoimidazo The transcript levels of MGMT, ERCC1, hMLH1 and hMSH2 (5,1-d)-as-tetrazine-8-carboxamide] and dacarbazine (1-3). were determined using reverse transcription-quantitative Alkylating agents form a variety of DNA adducts in polymerase chain reaction.
    [Show full text]
  • Targeting Autophagy Augments in Vitro and in Vivo Antimyeloma Activity of DNA-Damaging Chemotherapy
    Author Manuscript Published OnlineFirst on February 2, 2011; DOI: 10.1158/1078-0432.CCR-10-0890 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy Yaozhu Pan1,3, Ying Gao1,3, Liang Chen1,2, Guangxun Gao1, Hongjuan Dong1, Yang Yang1, Baoxia Dong1, Xiequn Chen1 1Department of Hematology, Xijing Hospital, Fourth Military Medical University; Xi’an, People’s Republic of China 2Department of Bioengineering, School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, People’s Republic of China Running head: autophagy and DNA-damaging chemotherapy in MM 3These authors contributed equally to this work. Key words: multiple myeloma; autophagy; apoptosis; DNA damage; xenograft model Corresponding author: Xiequn Chen, Department of Hematology, Xijing Hospital, Fourth Military Medical University, No.17 Changle West Road, Xi’an 710032, China; e-mail: [email protected]; [email protected] 1 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on February 2, 2011; DOI: 10.1158/1078-0432.CCR-10-0890 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Translational Relavance Multiple myeloma (MM) is a hematologic malignancy resulting from a clonal proliferation of plasma cells in the bone marrow. Although there have been major advances in the treatment of MM in recent years, it remains incurable mostly because of the development of drug resistance. Herein, we demonstrates that DNA-damaging agents (such as doxorubicin and melphalan) induced autophagy as a prosurvival mechanism in MM cells by engaging Bcl-2/Beclin1/Class III phosphatidylinositol 3-kinase complex.
    [Show full text]
  • High-Dose Mitoxantrone + Melphalan (MITO/L-PAM)
    Leukemia (2001) 15, 256–263 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity C Tarella1, F Zallio1, D Caracciolo1, A Cuttica1, P Corradini1,2, P Gavarotti1, M Ladetto1, V Podio3, A Sargiotto4, G Rossi5, AM Gianni6 and A Pileri1 1Dipartimento di Medicina e Oncologia Sperimentale, Divisione Universitaria di Ematologia; Serv. 3Univ. e 4Osped di Medicina Nucleare; 5Divisione Universitaria di Radioterapia-Azienda Ospedaliera S Giovanni Battista di Torino, Torino; and 6Unita` Trapianto Midollo, Ist Naz. Tumori, Milano, Italy Hematological and extrahematological toxicity of high-dose The ease deriving from the excellent tolerability of PBPC (hd) mitoxantrone (MITO) and melphalan (L-PAM) as condition- procedures probably slowed down the efforts aimed to look ing regimen prior to peripheral blood progenitor cell (PBPC) autograft was evaluated in 113 lymphoma patients (87 at dis- for innovative and possibly more effective conditioning regi- ease onset). Autograft was the final part of a hd-sequential mens. In fact, most autograft programs employed nowadays (HDS) chemotherapy program, including a debulkying phase are based on conditioning regimens designed several years (1–2 APO ± 2 DHAP courses) and then sequential adminis- ago, such as TBI + cyclophosphamide (CY), or regimens con- tration of hd-cyclophosphamide, methotrexate (or Ara-C) and taining nitrosurea or melphalan (L-PAM), such as BEAM, CBV etoposide, at 10 to 30 day intervals. Autograft phase included: or BEAC.17–21 Looking for a better conditioning regimen, one (1) hd-MITO, given at 60 mg/m2 on day −5; (2) hd-L-PAM, given at 180 mg/m2 on day −2; (3) PBPC autograft, with a median of should not only consider the antitumor activity of a given drug 11 × 106 CD341/kg, or 70 × 104 CFU-GM/kg, on day 0.
    [Show full text]
  • High-Dose Cyclophosphamide Or Melphalan with Escalating Doses of Mitoxantrone and Autologous Bone Marrow Transplantation for Refractory Solid Tumors Paula O
    [CANCER RESEARCH 49. 4654-4658. August 15. 1989] High-Dose Cyclophosphamide or Melphalan with Escalating Doses of Mitoxantrone and Autologous Bone Marrow Transplantation for Refractory Solid Tumors Paula O. M. Mulder,1 Dirk T. Sleijfer, Pax H. B. Willemse, Elisabeth G. E. de Vries, Donald R. A. Uges, and Nanno H. Mulder Divisions of Intensive Care [P. O. M. M.] and Medical Oncology-¡D.T. S., P. H. B. W., E. G. E. d. K, N. H. M.], Department of Internal Medicine, and Department of Pharmacy [D. R. A. U.J, University Hospital, 9713 EZ Groningen, The Netherlands ABSTRACT In the current clinical trial adult patients with disseminated As the dose-limiting toxicity of mitoxantrone is hematological, the solid tumors received a regimen of escalating doses of mito xantrone in combination with high-dose cyclophosphamide on drug is suitable for dose escalation and use in intensive chemotherapy three consecutive days followed by ABMT.2 followed by autologous bone marrow rescue. Adult patients with therapy- resistant solid tumors received a regimen of high-dose cyclophosphamide The objectives of our study were: determination of the max (7 g/m2) and escalating doses of mitoxantrone in dose steps of 30,45, 60, imum tolerated dose of mitoxantrone that can be given in and 75 mg/m2. Both drugs were given i.v. on 3 consecutive days. Despite combination with a fixed high-dose of cyclophosphamide; de the addition of mesnum (3.5 to 7 g/m2), hemorrhagic cystitis occurred on termination of the extramedullary toxicity; assessment of the the second day in four of eight patients, irrespective of the mesnum or antitumor activity of the regimen; and determination of the mitoxantrone dose.
    [Show full text]
  • Melphalan (Alkeran®) (“MEL Fa Lan”)
    Melphalan (Alkeran®) (“MEL Fa lan”) How drug is given: by mouth Purpose: to kill cancer cells in multiple myeloma, ovarian cancer, and other cancers How to take the drug by mouth • Take this medication on an empty stomach (at least 1 hour beFore or 2 hours after food). Taking it before a meal or at bedtime may decrease nausea. • Swallow each tablet whole; do not crush or chew them. If you are unable to swallow the tablet, the pharmacist will give you specific instructions • IF you miss a dose, take it as soon as possible. However, iF it is almost time For your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double dose. • Wash hands after taking the medication. Avoid handling crushed or broken tablets. Storage • Store this medicine in the refrigerator, away From light. Keep this medicine in its original container, out oF the reach oF children and pets. Things that may occur during treatment 1. You may have nausea, vomiting, and/or loss oF appetite. Nausea and vomiting may begin soon after the drug is given and may last more than 24 hours. You may be given medicine to help with this. 2. Your blood cell counts may drop. This is known as bone marrow suppression. This includes a decrease in your: • Red blood cells, which carry oxygen in your body to help give you energy • White blood cells, which Fight inFection in your body • Platelets, which help clot the blood to stop bleeding If you have a fever of 100.5°F (38°C) or higher, chills, a cough, or any bleeding problems, tell your doctor or nurse right away.
    [Show full text]